Halo Technology Holdings Inc (NASDAQ:HALO) Sentiment Change Report

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Logo

Sentiment for Halo Technology Holdings Inc (NASDAQ:HALO)

Halo Technology Holdings Inc (NASDAQ:HALO) institutional sentiment increased to 1.44 in Q1 2019. Its up 0.19, from 1.25 in 2018Q4. The ratio is positive, as 82 hedge funds increased and opened new holdings, while 57 reduced and sold their stock positions in Halo Technology Holdings Inc. The hedge funds in our partner’s database now hold: 115.20 million shares, down from 116.15 million shares in 2018Q4. Also, the number of hedge funds holding Halo Technology Holdings Inc in their top 10 holdings decreased from 2 to 1 for a decrease of 1. Sold All: 11 Reduced: 46 Increased: 55 New Position: 27.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company has market cap of $2.32 billion. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. It currently has negative earnings. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

The stock increased 0.19% or $0.03 during the last trading session, reaching $15.85. About 506,822 shares traded. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has declined 1.34% since August 16, 2018 and is downtrending. It has underperformed by 1.34% the S&P500.

Third Security Llc holds 33.85% of its portfolio in Halozyme Therapeutics, Inc. for 14.09 million shares. Bb Biotech Ag owns 8.32 million shares or 3.37% of their US portfolio. Moreover, First Light Asset Management Llc has 3.08% invested in the company for 1.47 million shares. The California-based Snyder Capital Management L P has invested 2.15% in the stock. Doheny Asset Management Ca, a California-based fund reported 146,070 shares.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

Ratings analysis reveals 67% of Halozyme’s analysts are positive. Out of 3 Wall Street analysts rating Halozyme, 2 give it “Buy”, 1 “Sell” rating, while 0 recommend “Hold”. The lowest target is $18 while the high is $24. The stock’s average target of $21 is 32.49% above today’s ($15.85) share price. HALO was included in 5 notes of analysts from February 22, 2019. The rating was maintained by Cantor Fitzgerald on Friday, February 22 with “Buy”. The company was maintained on Friday, February 22 by Barclays Capital. JMP Securities maintained the shares of HALO in report on Tuesday, February 26 with “Buy” rating. The company was maintained on Thursday, February 28 by Cantor Fitzgerald.

More notable recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were published by: Finance.Yahoo.com which released: “Is Halozyme Therapeutics (NASDAQ:HALO) Weighed On By Its Debt Load? – Yahoo Finance” on August 06, 2019, also Globenewswire.com with their article: “ZAGG Reports First Quarter 2019 Results Nasdaq:ZAGG – GlobeNewswire” published on May 07, 2019, Nasdaq.com published: “Gear4 Introduces Lineup of Cases for Samsung Galaxy Note10 and Note10+ – Nasdaq” on August 08, 2019. More interesting news about Halozyme Therapeutics, Inc. (NASDAQ:HALO) were released by: Seekingalpha.com and their article: “Stocks To Watch: Trading Tariff Turbulence – Seeking Alpha” published on August 03, 2019 as well as Prnewswire.com‘s news article titled: “Halozyme Announces First Clinical Dosing In argenx’s Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology – PRNewswire” with publication date: July 17, 2019.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.